Analyst Price Targets — BCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 10:41 am | Jonathan Wolleben | JMP Securities | $25.00 | $6.97 | TheFly | BioCryst price target lowered to $25 from $27 at Citizens JMP |
| November 4, 2025 10:07 am | — | Barclays | $9.00 | $6.86 | TheFly | BioCryst price target lowered to $9 from $11 at Barclays |
| October 14, 2025 7:51 pm | — | RBC Capital | $15.00 | $6.42 | TheFly | BioCryst weakness presents 'compelling' buying opportunity, says RBC |
| October 14, 2025 7:21 pm | Maury Raycroft | Jefferies | $15.00 | $6.42 | TheFly | BioCryst price target raised to $15 from $14 at Jefferies |
| October 1, 2025 12:36 pm | — | Evercore ISI | $8.00 | $7.24 | TheFly | BioCryst downgraded to In Line from Outperform at Evercore ISI |
| August 6, 2024 5:31 am | Gena Wang | Barclays | $7.00 | $7.51 | TheFly | BioCryst price target raised to $7 from $6 at Barclays |
| August 5, 2024 4:01 pm | Maury Raycroft | Jefferies | $11.00 | $7.51 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies |
| November 2, 2022 6:28 am | Liisa Bayko | Evercore ISI | $16.00 | $12.39 | StreetInsider | UPDATE: Evercore ISI Upgrades BioCryst Pharma (BCRX) to Outperform |
| August 23, 2022 11:14 am | Gena Wang | Barclays | $14.00 | $14.33 | Pulse 2.0 | BioCryst (BCRX) Stock: $14 Target And Equal-Weight Rating |
| January 10, 2022 12:00 am | Ken Cacciatore | Cowen & Co. | $25.00 | $14.78 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $25 at Cowen on Orladeyo Sales Data |
Latest News for BCRX
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026.
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —
BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Polydex Pharmaceuticals (OTCMKTS:POLXF - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent
RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as…
Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 88.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology company's stock after selling 2,733,012 shares during the period. Assenagon
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.